References
- Avgoustakis K. Pegylated poly(lactide) and poly (lactide-co-glycolide) nanoparticles: Preparation, properties and possible applications in drug delivery. Current Drug Del 2004; 1: 321–33
- Beletsi A, Leontiadis L, Klepetsanis P, Ithakissios DS, Avgoustakis K. Effect of preparative variables on the properties of poly(dl-lactide-co-glycolide)-methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery. Int J Pharm 1999; 182: 187–97
- Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Abd Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Can Res 2004; 10: 8048–58
- Gref R, Minamitake Y, Peracchia MT. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600–3
- Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol Seminars Original Inves 2008; 26: 57–64
- Jain A, Jain SK. PEGylation: An approach for drug delivery. A review. Critical Rev Ther Drug Carrier Syst 2008; 25(5)403–44
- Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007; 24(9)1759–71
- Katsikogianni G, Avgoustakis K. Delivery of the p38 MAP kinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PE gylated drug–albumin conjugates using platinum(II)-based drug linker technology. J Nanosci Nanotech 2006; 6: 3080–6
- Khuller GK, Pandey R. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicro Chemother 2006; 57: 1146–52
- Koo YEL, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Ross BD, Kopelman R. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Del Rev 2006; 58: 1556–77
- Li Y, Ogris M, Wagner E, Pelisek J, Ruffer M. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: Preparation and in vitro evaluation. Int J Pharm 2003; 259: 93–101
- Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev Ind Pharm 2002; 28: 1–13
- Moss T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Mol Neurobiol 2000; 20: 77–95
- Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs 2009; 23(1)35–58
- Pygall SR, Whetstone J, Timmins P, Melia CD. Pharmaceutical applications of Confocal Laser Scanning Microscopy: The physical characterisation of pharmaceutical systems. Adv Drug Del Rev 2007; 59: 1434–52
- Soni V, Jain A, Khare P, Gulbake A, Jain SK. Potential approaches for drug delivery to the brain: Past, present, and future. Critical Rev Ther Drug Carrier Sys 2010; 27(3)187–236
- Soni V, Jain SK, Kohli DV. Program DYNAFIT for the analysis of enzyme kinetic data: Application to HIV proteinase. Am J Drug Del 2005; 3(3)155–70
- Soni V, Jain SK, Kohli DV. Transferrin coupled liposomes as drug delivery carrier for brain targeting of 5-florouracil. J Drug Target 2008; 16(1)73–8
- Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier. Eur J Pharm Biopharm 2009; 71: 251–6
- Visser CC, Stevanovic S, Voorwinden LH, Gaillard PJ, Crommelin DJA, Danhof M, De Boer AG. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 2004a; 12(3)145–50
- Visser CC, Voorwinden LH, Crommelin DJA, Danhof M, deBoer AG. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res 2004b; 21(5)761–9